Nymox Pharmaceutical Corporation (NYMXF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | - | 0 | - |
| Operating profit | $m | -4 | -1 | ||||||
| Net profit | $m | -12 | -13 | -7 | -9 | -4 | - | -2 | - |
| EPS reported | $ | -0.05 | -0.02 | ||||||
| Operating cashflow per share | $ | -0.03 | -0.03 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.03 | -0.03 | ||||||
| Free cash flow | $m | -3 | -1 | ||||||
| Net debt | $m | -0 | -0 | ||||||
| Book value equity | $m | -7 | -7 | ||||||
| Book value per share | $ | -0.07 | -0.07 | ||||||
| Number of shares | m | 93.67 | 94.23 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1.38 | -0.57 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -3.60 | -5.38 | ||||||
| EV/EBITDA LTM | x | -2.18 | -2.71 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -47.96% | -8.56% | ||||||
| FCF Yield | % | -27.77% | -18.57% | ||||||
| Quality | |||||||||
| ROE | % | +66.30% | +90.31% | ||||||
| ROIC | % | +63.22% | +63.22% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.02 | 0.02 | ||||||
| EBIT/Net interest | x | -18.95 | -18.95 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | 0.01 | 0.01 | ||||||
| Gross debt/equity | x | -0.00 | -0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma. Beyond its drug pipeline, Nymox develops and offers two diagnostic products: NicAlert, which identifies tobacco usage, and TobacAlert, designed to detect exposure to secondhand smoke. The company is also actively engaged in developing treatments for Alzheimer's disease. Nymox Pharmaceutical Corporation was established in 1989 and maintains its headquarters in Nassau, the Bahamas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Nymox Pharmaceutical Corporation (NYMXF)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma. Beyond its drug pipeline, Nymox develops and offers two diagnostic products: NicAlert, which identifies tobacco usage, and TobacAlert, designed to detect exposure to secondhand smoke. The company is also actively engaged in developing treatments for Alzheimer's disease. Nymox Pharmaceutical Corporation was established in 1989 and maintains its headquarters in Nassau, the Bahamas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free